- Home
- FMN vs IGMS Comparison
FMN vs IGMS Comparison
Compare FMN & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMN
- IGMS
- Stock Information
- Founded
- FMN 2002
- IGMS 1993
- Country
- FMN United States
- IGMS United States
- Employees
- FMN N/A
- IGMS N/A
- Industry
- FMN Investment Managers
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- FMN Finance
- IGMS Health Care
- Exchange
- FMN Nasdaq
- IGMS Nasdaq
- Market Cap
- FMN 86.2M
- IGMS 82.1M
- IPO Year
- FMN N/A
- IGMS 2019
- Fundamental
- Price
- FMN $10.90
- IGMS $1.23
- Analyst Decision
- FMN
- IGMS Hold
- Analyst Count
- FMN 0
- IGMS 8
- Target Price
- FMN N/A
- IGMS $6.14
- AVG Volume (30 Days)
- FMN 22.8K
- IGMS 190.3K
- Earning Date
- FMN 01-01-0001
- IGMS 05-07-2025
- Dividend Yield
- FMN 3.86%
- IGMS N/A
- EPS Growth
- FMN N/A
- IGMS N/A
- EPS
- FMN N/A
- IGMS N/A
- Revenue
- FMN N/A
- IGMS $2,679,000.00
- Revenue This Year
- FMN N/A
- IGMS $106.64
- Revenue Next Year
- FMN N/A
- IGMS $68.35
- P/E Ratio
- FMN N/A
- IGMS N/A
- Revenue Growth
- FMN N/A
- IGMS 25.77
- 52 Week Low
- FMN $9.09
- IGMS $1.11
- 52 Week High
- FMN $11.31
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- FMN 44.81
- IGMS 40.11
- Support Level
- FMN $10.77
- IGMS $1.11
- Resistance Level
- FMN $11.00
- IGMS $1.31
- Average True Range (ATR)
- FMN 0.07
- IGMS 0.08
- MACD
- FMN 0.00
- IGMS 0.04
- Stochastic Oscillator
- FMN 56.52
- IGMS 61.54
About FMN Federated Hermes Premier Municipal Income Fund
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.